<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265239</url>
  </required_header>
  <id_info>
    <org_study_id>310</org_study_id>
    <nct_id>NCT00265239</nct_id>
  </id_info>
  <brief_title>Pilot Study of Edaravone to Treat Acute Myocardial Infarction</brief_title>
  <official_title>Effects of Edaravone in Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kumamoto University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kumamoto University</source>
  <brief_summary>
    <textblock>
      Early reperfusion therapy has improved the clinical outcomes of patients with acute
      myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion
      injuries. There is now increasing evidence that reactive oxygen species cause reperfusion
      injury. This study was designed to examine the effects of edaravone, a novel free radical
      scavenger, in patients with AMI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initial AMI patients were randomly assigned to receive 30 mg of edaravone or a placebo
      intravenously just before reperfusion. We compared infarct size, using serial determination
      of serum biomarkers and Q wave formations, and the incidence of reperfusion arrhythmia
      between the groups. Cardiovascular event-free curves were estimated by Kaplan-Meier method.
      In addition, we determined serum thioredoxin levels, an oxidative stress marker, to assess
      the antioxidant effect of edaravone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Death</measure>
    <time_frame>415±32 days</time_frame>
    <description>number of cardiac death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nonfatal Myocardial Reinfarction</measure>
    <time_frame>415days</time_frame>
    <description>number of nonfatal myocardial reinfarction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Refractory Angina Pectoris</measure>
    <time_frame>415days</time_frame>
    <description>number of refractory angina pectoris</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nonfatal Ischemic Stroke</measure>
    <time_frame>415days</time_frame>
    <description>number of nonfatal ischemic stroke</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Edaravone Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Placebo Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>edaravone</intervention_name>
    <description>intravenous administration of 30mg Edaravone just before reperfusion therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Initial AMI patients admitted to the investigators' institution within 6 hours of
             symptom onset and treated primary percutaneous coronary intervention.

        Exclusion Criteria:

          -  Renal insufficiency defined as serum creatinine &gt; 1.2 mg/dl and altered hepatic
             function defined as serum asparate aminotransferase &gt; 50 IU/L, alanine
             aminotransferase &gt; 50 IU/L and total bilirubin &gt; 1.2 mg/dl.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisao Ogawa, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2005</study_first_submitted>
  <study_first_submitted_qc>December 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2005</study_first_posted>
  <results_first_submitted>May 19, 2014</results_first_submitted>
  <results_first_submitted_qc>September 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2014</results_first_posted>
  <last_update_submitted>September 12, 2014</last_update_submitted>
  <last_update_submitted_qc>September 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2014</last_update_posted>
  <keyword>Edaravone</keyword>
  <keyword>Randomized Control Trial</keyword>
  <keyword>ST-Elevation Myocardial Infarction</keyword>
  <keyword>Coronary Angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylmethylpyrazolone</mesh_term>
    <mesh_term>Antipyrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Edaravone Group</title>
          <description>Edaravone Group
edaravone: intravenous administration of 30mg Edaravone just before reperfusion therapy</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Placebo Group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Edaravone Group</title>
          <description>Edaravone Group
edaravone: intravenous administration of 30mg Edaravone just before reperfusion therapy</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Placebo Group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="2"/>
                    <measurement group_id="B2" value="63" spread="2"/>
                    <measurement group_id="B3" value="63" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Death</title>
        <description>number of cardiac death</description>
        <time_frame>415±32 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Edaravone Group</title>
            <description>Edaravone Group
edaravone: intravenous administration of 30mg Edaravone just before reperfusion therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo Group</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death</title>
          <description>number of cardiac death</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nonfatal Myocardial Reinfarction</title>
        <description>number of nonfatal myocardial reinfarction</description>
        <time_frame>415days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Edaravone Group</title>
            <description>Edaravone Group
edaravone: intravenous administration of 30mg Edaravone just before reperfusion therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo Group</description>
          </group>
        </group_list>
        <measure>
          <title>Nonfatal Myocardial Reinfarction</title>
          <description>number of nonfatal myocardial reinfarction</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Refractory Angina Pectoris</title>
        <description>number of refractory angina pectoris</description>
        <time_frame>415days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Edaravone Group</title>
            <description>Edaravone Group
edaravone: intravenous administration of 30mg Edaravone just before reperfusion therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo Group</description>
          </group>
        </group_list>
        <measure>
          <title>Refractory Angina Pectoris</title>
          <description>number of refractory angina pectoris</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nonfatal Ischemic Stroke</title>
        <description>number of nonfatal ischemic stroke</description>
        <time_frame>415days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Edaravone Group</title>
            <description>Edaravone Group
edaravone: intravenous administration of 30mg Edaravone just before reperfusion therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo Group</description>
          </group>
        </group_list>
        <measure>
          <title>Nonfatal Ischemic Stroke</title>
          <description>number of nonfatal ischemic stroke</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>adverse events were only collected during the therapy period, up to 2 weeks</desc>
      <group_list>
        <group group_id="E1">
          <title>Edaravone Group</title>
          <description>Edaravone Group
edaravone: intravenous administration of 30mg Edaravone just before reperfusion therapy</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Placebo Group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kenichi Tsujita</name_or_title>
      <organization>Kumamoto University</organization>
      <phone>+81-96-373-5175</phone>
      <email>tsujita@kumamoto-u.ac.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

